SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| KIVEXA film-coated tablet | 600,300 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 1676.80 | NCE · Prescription | Glaxo Saudi Arabia Ltd | Valid |
Indications — CHI Daman Drug Formulary
HUMAN IMMUNODEFICIENCY VIRUS
US FDA United States — FDA approvals (Drugs@FDA)
EMA European Union — centrally authorised medicines
Kivexa ViiV Healthcare BV · Authorised · authorised 16 Dec 2004 · ATC J05AR02
Therapeutic indication (EMA)
Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg. Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | ABACAVIR-LAMIVUDINE 600-300 MG | $1.48365 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.4.2.5. Fixed-dose combinations of antiretrovirals · core
Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.